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The purpose of the present study is to estimate the impact of pharmaceutical spending
reduction on public revenue, based on data from the national health accounts as well as
on reports of Greece’s organizations. The methodology of the analysis is structured in two
basic parts. The first part presents the urgency for rapid cutbacks on public pharmaceuti-
cal costs due to the financial crisis and provides a conceptual framework for the contribu-
tion of the Greek pharmaceutical branch to the country’s economy. In the second part, we
perform a quantitative analysis for the estimation of multiplier effects of public pharmaceu-
tical expenditure reduction on main revenue sources, such as taxes and social contribu-
tions. We also fit projection models with multipliers as regressands for the evaluation of the
efficiency of the particular fiscal measure in the short run. According to the results, nearly
half of the gains from themeasure’s application is offset by financially equivalent decreases
in the government’s revenue, i.e., losses in tax revenues and social security contributions
alone, not considering any other direct or indirect costs. The findings of multipliers’ high
value and increasing short-term trend imply the measure’s inefficiency henceforward and
signal the risk of vicious circles that will provoke the economy’s deprivation of useful
resources.
Keywords: public pharmaceutical expenditure, fiscal consolidation, multipliers, unemployment, Greece, revenue
Introduction
Detecting sources of vulnerability in the economy timely, especially in unstable financial conditions,
is a rational act keyed to the design of sound government fiscal policies on the basis of well-reasoned
decisions. The process of dissolving uncertainty requires the analytical study of national account
data and economic flows and can be strengthened through the use of fiscal statistics tools [see
Government Finance Statistics Manual 2001 (1)].
Abbreviations:DT, direct taxes; PPE, public pharmaceutical expenditure; PR, revenue; RL, revenue losses, SSC, social security
contributions; TRL, total revenue losses; UB, unemployment benefits; VATL, value added tax losses.
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The Greek Government, in order to deal with the dramatic
economic fluctuations caused by the global financial crisis (2),
proceeded to a great number of fiscal policies in comparison with
the other European Union (EU) member states (3). The drastic
adjustment of Greece’s economy to the macroeconomic fluctu-
ations and stresses was designed with a view to cutting public
spending, rather than raising revenues (4, 5) and, as in many EU
countries, hinged to a great extent on reforms of the health sector
(6–8). Thus, a series of measures were implemented, including,
among others, health workforce downsizing, the reduction in fees
paid to health providers, the lowering of pharmaceutical prices,
and the setting of pharmaceutical budget equal to a fixed share
of the gross domestic product (GDP) (as presented in paragraph
2.1.1.2).
The impact of many of these interventions on the real Greek
economy remains unexplored, forming a novel field of applied
fiscal statistics which the present work attempts to deal with.
It focuses on a pharmaceutical policy intervention with tangi-
ble accounting outcomes and de jure dependence on economic
growth indices (as explained in the following paragraphs), aiming
to address a particular angle of the sensitive topic of restrictive
healthcare policies’ financial effects on the real economy’s flows.
Materials and Methods
Problem Formulation: Conceptual Framework
Curtailing Public Pharmaceutical Expenditure in
Greece: A Fiscal Consolidation Strategy
Urgency of measures
Upon the advent of the financial crisis in 2008, Greece was already
placed at a disadvantaged financial situation due to its high general
government gross debt, the highest among EU countries1. From
2008 to 2013, the Greek economy suffered a sharp shrinkage: the
GDP with a year-on-year fall of up to 7% (Figure 1) fell by 22%
over the same period (in per capita terms)2 and about one-fifth of
the aggregate production was lost [reaching even 2/3 in specific
economy sectors, such as the Structure (9)]. Private investments
and consumption were reduced by AC27.4 and AC16.3 bn (or 17.6
and 9.1%), respectively (9), whereas unemployment climbed to
27.4% (first quarter of 2013) from 7.6%, affecting mostly young
people and women. The prolonged election period (May–June
2012) deteriorated further the business expectations and con-
sumers’ confidence (10, 11).
In Greece, small deviations from the bottom of the recession
were observed from the fourth quarter of 2012 onward, driven
mostly by the negotiation with the European Commission (EC),
the EuropeanCentral Bank (ECB) and the InternationalMonetary
Fund (IMF), the materialization of commitments on the basis of
the Memorandum of Understanding (MoU) and the Memoran-
dum of Economic and Financial Policies, and the withdrawal of
AC34.4 bn from the support mechanism (10).
1Eurostat. General government gross debt – annual data. Available from: http://
ec.europa.eu/eurostat/tgm/refreshTableAction.do?tab=table&plugin=1&pcode=
teina225&language=en. Accessed 22 February 2015.
2Based on the authors’ calculations. Source of data: Eurostat. Available from:
http://ec.europa.eu/eurostat/tgm/table.do?tab=table&init=1&language=
en&pcode=tec00114&plugin=1. Accessed 16 June 2015.
FIGURE 1 | GDP year-on-year changes in Greece (2008–2013).
FIGURE 2 | Public pharmaceutical expenditure of Greece (2000–2014).
The fiscal consolidation strategy of 2014 entailed the applica-
tion ofmeasures for debt reduction to 174.8%, for primary surplus
1.6%, and for growth 0.6% of the GDP3.
All economies deal with finite resources, the allocation ofwhich
determines the selection among competing strategies and inter-
ventions (12). However in the case of Greece, under the IMF loan
conditions (13) and according to the MoU, specific economic
sectors, such as healthcare, were identified early on, as fields of
immediate intervention for fiscal consolidation (14, 15). Public
pharmaceutical expenditure (PPE) in particular, having exhibited
a sharp expansion in the pre-crisis period (Figure 2), became the
capping stone of the country’s effort for a rapid cost-containment
in healthcare.
Regulatory framework
Since 2010, a significant number of measures have been imple-
mented for the restriction of excess public pharmaceutical expen-
diture which stemmed from the over-prescription of branded
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drugs (16). These measures focused on the demand (e.g., gener-
ics prescribing, development of therapeutic protocols, etc.) or
the supply side (e.g., reimbursement lists for pharmaceuticals,
external reference pricing, etc.) of the pharmaceuticalmarket (17).
In 2012, a mechanism referred to as clawback, for the automatic
refund of amounts that excess the state’s public pharmaceutical
expenditure budget is instituted by law (laws 4052 and 4093, g.g.
A41 and A222, respectively4). Following a ministerial decree (g.g.
B2243/20144), the ceiling for pubic pharmaceutical expenditure is
specified at 1% of the country’s GDP, which is applicable as from
2014.
Accounting and employment outcomes
Over the years 2009–2013, public pharmaceutical expenditure has
been reduced by AC2.7 bn (or 50%) (Figure 2), which corresponds
to 11% of the total amount of reduction of aggregate public
expenditure (that is, AC24.9 bn) (18). At the same time, according
to the Vocational Insurance Fund of pharmaceutical corporations’
employees, the workforce of the medicine branch (corporations
and pharmacies) was reduced from 31,100 to 21,500, that is, by
30.9%, yielding a loss of 3.5 job positions for each million cut [i.e.,
(21,500–31,100)/2,740].
Contribution of the Pharmaceutical Branch to the
Greek Economy
The present section draws on published data of Greek organiza-
tions offering an overview of the pharmaceutical sector5.
Public pharmaceutical expenditure (PPE) is a basic compo-
nent of the country’s economy. In per capita terms, it consists
around 44% of the public health expenditure6 and 1.9% of GDP
(2011) (19).
Considering production value, extroversion, and impact on
other sectors of the economy (externalities), the pharmaceutical
sector, represents one of the most dynamic sectors of the Greek
economy, including 421 pharmaceutical marketing authorization
holders, 124 pharmaceutical wholesalers, and 11,315 pharmacies.
In terms of gross value added, the pharmaceutical sector has
followed an upward trend in the past decade, reaching 9.6%
of total manufacturing production, which represents one of the
highest rates in the EU, after Slovenia (12.7%) and Denmark
(10.4%). Indeed, during the period 2000–2010, the industry not
only increased the percentage of manufacturing production in
Greece, but also presented the highest average annual increase
in the gross value added among EU countries (by about 7%,
from 2.7% in 2000 to 9.6% in 2010). In 2010, the production and
marketing of pharmaceutical products contributed to the Greek
economy by AC7.5 bn which corresponds to 3.4% of the GDP.
Furthermore, the industry has invested significant amounts on
research and development over time (for instance, AC85 and AC88
million in 2011 and 2012, respectively).
In terms of employment, onlywithin a year (2010), 132,787 jobs
were offered, while total tax revenues from the pharmaceutical
4Source: http://www.et.gr. Accessed 16 June 2015.
5Institute of Social and Preventive Medicine of Greece (IKPI). The impact of
Pharmaceutical Expenditure Reduction on Public Revenues Athens, April 2014
6Calculation of the authors. Source: http://dx.doi.org/10.1787/health-data-en;
WHO Global Health Expenditure Database data-en.
sector amounted to AC400.9 million. Exports of pharmaceutical
products had the fourth largest share in total manufacture exports
(6% on average over the years 2000–2010), with the largest per-
centage of exports being directed to the EU member states. High
levels of demand have also been generated on behalf of South
Africa, Turkey, Switzerland, and Brazil.
Another area of contribution of the pharmaceutical sector to
the Greek economy is that of public debt management, through
the settlement of outstanding debts via the bond market and the
maturity of public obligations toward pharmaceutical companies
(law 4046, g.g. A28/2012 and article 12 of law 4052, g.g. A41/2012
as revised by law 4093, g.g. A222/20127).
The pharmaceutical sector has additionally exerted a consid-
erable impact on the function of other sectors, such as Adver-
tising, which in recent years has suffered a sharp decline of its
total turnover. Total advertising costs of the pharmaceutical sec-




Considering the economy’s ongoing shrinkage due to the eco-
nomic crisis, the issue of applying a health measure that depends
on the GDP is challenging. In this respect, the present study
attempts to assess the impact of setting public pharmaceutical
economy equal to a small share of the (gradually diminishing)
GDP on the Greek economy.
In particular, the impact is assessed in terms of the losses
in taxes and social security contributions that derive from the
reduction of turnover and the increase of unemployment in the
pharmaceutical industry and pharmacies. It is worth noting herein
that only the direct budgetary impact of reducing public phar-
maceutical expenditure is investigated, without considering the
potential impact on other sectors or economic consequences,
such as the problematic access to treatments due to the ongoing
shrinkage of the market (20) and the delays in reimbursement for
retail pharmacies (21) aswell as the consequent productivity losses
related to increase in the length of hospitalization (22, 23) and job
absenteeism (24).
Working Assumption
In the context of the present analysis we made the working
assumption that as pharmaceutical expenditure decreases, the
(negative) impact on public revenue is expected to grow, because,
in the early years of the measure’s application, the decreases will
primarily relate to waste and unnecessary spending.
Quantitative Analysis
We took into consideration the vulnerability of two categories
of economic flows. The first corresponds to the annual public
cost that is generated by the provision of pharmaceutical care in
Greece. The second refers to the net worth resulting from tax
collection as dominant share of revenue for government (1), as
well as the compulsory transfer of social security contributions.
We developed a calculus for measuring the lost governmental
revenues due to the reduction in private and corporate tax
7Source: http://www.et.gr. Accessed 12 April 2015.
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amounts and social security contributions [formulas (1)–(1.3)].
Only the direct budgetary impact of the measure is investigated,
not taking into consideration the putative impact on other pro-
duction sectors, as specified earlier.
For the estimation of the effect of the fiscal policy under analysis
(namely the PPE curtailment to 1% of the GDP) on the economy,
multipliers are used as common quantitative tools. The multi-
plier is computed dividing cumulative losses of revenues by the
observed reduction in the PPE in the time domain 2009–2013
[formula (2)].
We also perform sensitivity analysis for the values of the multi-
pliers. Thresholds of the multiplier are derived by simply leaving
indirect taxes (VAT amounts) and unemployment benefits out of
the total loss equation [formula (1)].
Finally, three naïve estimating models for the multipliers are
fitted to the data, a linear (Eq. 3), an exponential growth (Eq. 4)
and a quadratic trend (Eq. 5). Projections on 2015 are performed,









dPRn = PRt0   PRtn (1.1)
where TRLtn is the total losses in public revenue between years
t0 and tn, with tn–t0= n, RLti is the loss of government revenue
in the year ti, i= 1, 2, : : :, n from the previous year, UBti is the
unemployment benefits in year ti, i= 1, 2, : : :, n, and PRk is the
revenue in the tk year, k= 0, 1, 2, : : :, n, defined as follows:
PR = DT+ VATL+ SSC (1.2)
DT = DT1 +DT2 (1.3)
where DT is the direct taxes, DT1 is the losses in personal income
taxes in year t, DT2 is the losses in corporate income taxes in year
t, VATL is the value added tax losses, i.e., losses in indirect taxes
in year t, and SSC is the social security contributions.
mt = TRLtdPPE1
(2)
where mt is the value of the multiplier in the year t, TRLt is the
total estimated revenues loss in the year t, and dPPE1 is the size of
annual cutting down on PPE between two consecutive years.
bmt = a + b  t (3)
bmt = c  dt (4)
bmt = e+ f  t + g  t2 (5)
where bmt is the estimated value of the multiplier in the year t, and
a, b, c, d, e, f, g coefficients with a, b, c, e, f, g 2 R, d 2 R+.
Results
Total Losses
Table 1 presents the estimated annual losses in public rev-
enues that are caused by the downsizing of the pharmaceutical
market.
Total losses of revenues equalAC453million. Nearly half (41.6%)
of these losses are observed in the period 2012–2013.
Since dPPE2013 equals AC400 million (Figure 2) and TRL2013
equals AC188.5 million (Table 1), the multiplier is estimated at
0.47 for the year 2013. Based on this estimation, AC100 million of
PPE curtailments are expected to generate losses of AC47 million
in public revenues.
Figure 3 depicts estimations of the multiplier for the period
2009–2013 and combines it with information on public pharma-
ceutical expenditure and losses in public revenues for the same
period.
FIGURE 3 | Public pharmaceutical expenditure changes in Greece and
the multiplier (2009–2013).
TABLE 1 | Losses per year in government revenues due to the public pharmaceutical expenditure curtailment (2009–2013).
Revenue loss category Absolute change (in AC million)
2010–2009 2011–2010 2012–2011 2013–2012 2013–2009
Direct taxes (DT) 73:78 37:68 77:15 75:37 263:98
Indirect taxes (VATL) 2:50 5:27 4:26 17:75 29:79
Social security contributions (SSC) 9:50 20:05 16:21 67:55 113:31
Subtotal-RL 85:78 63:00 97:63 160:67 407:08
Unemployment benefits (UB) 9:58 0:48 8:14 27:78 45:98
Total-TRL 95:36 63:48 105:77 188:45 453:06
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FIGURE 4 | Projection of the multiplier based on linear trend,
exponential growth curve, and quadratic trend models.
Sensitivity Analysis
The derived threshold for the estimated multiplier is 0.35 in 2013
meaning that for every AC100 million of reduction in the PPE, the
losses in public revenues are anticipated to beAC35million at least.
Projections
Results based on Eqs 3–5 are depicted in Figure 4. According to
the linear and exponential growth trends, the multiplier exceeds
0.5 in 2015, which implies the counterbalance of PPE curtailment
by 50% at least. With the quadratic model, the multiplier reaches
and exceeds the value 1.0 in 2014 and 2015, respectively.
Discussion
Contribution of the Analysis
Analysts in Greece have substantiated the pharmaceutical sector’s
contribution to the Greek economy on the basis of its high partial
multipliers on GDP (2.43), gross value added (2.56), employment
(2.48), as well as tax revenues (1.55), compared to other sectors,
such as tourism and shipping8. In the context of this analysis,
we strengthen the existing theoretical framework focusing on an
interventionwhichwas adopted as a suppressivemeasure of excess
public pharmaceutical spending. Instead of studying the gains
earned from the pharmaceutical sector, we reverse the problem,
by assessing the losses stemming from its exhaustion, which to
the notion of the authors is an original approach in the field of
pharmaceutical policy.
Analytically, this study deployed a simplistic multiplier-based
tool for evaluating the impact of a fiscal measure in the time
domain 2010–2013 and further, for estimating its dynamics in the
near future. This period is short, yet it isolates the crucial historical
(i.e., political and institutional) events that are instrumental for the
evolution of public pharmaceutical expenditure, namely the MoU
8Foundation for Economic and Industrial Research (IOBE). Economic footprint
of production and distribution of pharmaceutical products in the Greek economy.
Athens, January 2013.
and the country’s major healthcare reform (that established elec-
tronic prescribing in 20109 and integrated the health branches of
social security funds into a single health care provider in 201110).
Key Findings
In the present analysis, we highlighted the weaknesses and short-
term risks that accompany the restrictions imposed on the state’s
expenditures for pharmaceutical care. Based on the calculated
values of the multiplier, a considerable share (35–47%) of the
outcome of pharmaceutical spending cutback is expected to be
counterbalanced by the yielded losses in public revenues (taxes
and contributions). The multiplier increases sharply to 0.47 in
2013, complying with the working assumption that the applica-
tion of a restrictive pharmaceutical policy is expected to have a
bounded period of efficiency, after which further reductions in
PPE shall have repercussions on public revenues and the economy
as a whole.
The projection procedure indicated that the effects of the
applied measure on the GDP are sizeable enough to make the
intervention obsolete in the near future. The linear and the expo-
nential growth approach yielded more conservative and similar
results. On the contrary, the quadratic trend model generated
a sharp projection beyond the value “1,” from 2014 onward.
This outcome could be thought of as extreme, yet it is com-
patible with similar assessments from the literature, regarding
government spendingmultipliers’ propensity to increase, reach or
exceed the value “1,” under certain circumstances, in economic
downturns (25).
Conclusion
The pharmaceutical market, an already regulated sector due to
the existing external reference pricing system (26), is important
for yielding net worth in the Greek economy. Unambiguously,
pharmaceutical policies have so far enabled the rationalization
of public health expenditures. However, the activation of the
clawback mechanism as explained herewith has important side
effects, such as the increase of unemployment and the reduction
in main sources of public revenue, which undermine the values
of solidarity in financing, equity of access, and the provision of
high-quality health care (27).
Prospects of Further Analysis
The compilation of healthcare data and the subsequent broaden-
ing of time series will allow further development of estimation
and forecasting tools. In this context, applying multiplier-based
analyses to other areas of health policy intervention is considered
a reliable methodological vehicle for taking policy-makers a step
forward in evidence-based healthcare decision making.
9Law 3982 “Electronic recording and processing of prescriptions and medical
examinations,” g.g. 189/2010. Available from: http://www.et.gr. Accessed 10 June
2015.
10National Organisation for Health Care Services Provision (EOPYY). Law 3918
“Structural reforms of the health system and other provisions,” g.g. A31/2011.
Available from: http://www.et.gr. Accessed 10 June 2015.
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